Analysis
Corxel Pharmaceuticals will go public in the US through a merger with Amanat Acquisition Corp (Nasdaq: AMAN), a healthcare-focused blank-check company, according to a business combination agreement both companies' boards approved and disclosed on October 25, 2026. The combined company will list on the Nasdaq Capital Market under a new name and ticker, both still to be announced, with closing expected in the first half of 2027.
Deal structure
Amanat's trust account holds approximately $75 million, and a PIPE financing -- oversubscribed, with named participants including RTW Investments, NEA, SR One, RA Capital Management, and Invus -- is expected to raise approximately $300 million in gross proceeds.
“Total expected gross proceeds, trust plus PIPE, come to roughly $377 million before transaction costs, assuming no Amanat shareholder redemptions.”
Total expected gross proceeds, trust plus PIPE, come to roughly $377 million before transaction costs, assuming no Amanat shareholder redemptions. Leerink Partners is lead placement agent for the PIPE and capital markets advisor to Amanat, alongside Evercore ISI, Guggenheim Securities, Cantor, and LifeSci Capital as placement agents.
What Corxel is developing
Corxel's lead candidate, CX11, is a once-daily oral small-molecule GLP-1 receptor agonist in development for obesity and type 2 diabetes. In a US Phase 2 obesity trial, mean body-weight reduction reached up to 11.5% at week 36. Nausea occurred in 33% to 34% of participants across dose cohorts, with vomiting in 12% to 16%, diarrhea in 4% to 12%, and constipation in 2% to 12%; no severe gastrointestinal events were reported, and GI-related discontinuation was 5.0%. Corxel says it aligned with the FDA on Phase 3 design after an end-of-Phase-2 meeting and plans a global Phase 3 program, funded in part by this raise. A second candidate, CX12, is a preclinical oral amylin receptor agonist, with an IND filing targeted for the first half of 2027.
That puts Corxel in one of biotech's most crowded and lucrative categories: Novo Nordisk's Wegovy and Eli Lilly's Zepbound dominate the injectable GLP-1 obesity market today, while oral challengers including Viking Therapeutics, Structure Therapeutics, and Metsera are racing toward the same convenience advantage Corxel is chasing.
Why the SPAC route, not a traditional IPO
Pulse has tracked a steady stream of biotechs choosing to price traditional IPOs even as AI mega-valuations wobble, including Lycia Therapeutics' upsized offering. A SPAC merger is a different path -- typically faster to execute and less exposed to the week-to-week volatility of a traditional roadshow, but historically associated with weaker post-merger stock performance across the broader SPAC boom-and-bust cycle of the early 2020s. That history is a real caveat for any investor evaluating Corxel's PIPE terms against a comparable traditional biotech IPO. Corxel's current US management will keep running the business while Amanat searches for a US-based CEO to lead the combined company, a detail that adds execution risk on top of the usual SPAC redemption uncertainty.
What to watch
Whether Amanat shareholders redeem a meaningful share of the trust before closing, how Corxel's Phase 1b higher-dose data due in the first half of 2027 reads against Viking's and Metsera's oral candidates, and what name and ticker the combined company picks before listing.
